Overview
A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Indication
用于皮肤癌及鲍温病、牛皮癣，男性尿道尖锐湿疣等皮肤病。可治疗消化道肿瘤、口腔癌。可诊断和治疗膀胱癌、尿路上皮肿瘤。能阻止血管成形术后在狭窄。
Associated Conditions
- Actinic Cheilitis
- Actinic Keratoses of the face
- Actinic Keratoses of the scalp
- Actinic Keratosis (AK) of the Upper Extremity
- Basal Cell Carcinoma (BCC)
- Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)
- Glioma
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/07/08 | Not Applicable | Recruiting | Sherrif Ibrahim | ||
2025/06/26 | Phase 1 | Not yet recruiting | |||
2025/04/02 | Phase 2 | Not yet recruiting | Costas Hadjipanayis | ||
2024/12/24 | Phase 4 | Recruiting | Psoriasis Treatment Center of Central New Jersey | ||
2024/11/07 | Phase 2 | Not yet recruiting | |||
2024/03/13 | Phase 1 | Recruiting | |||
2024/02/12 | Phase 1 | Withdrawn | |||
2023/12/07 | Phase 3 | Recruiting | Lee's Pharmaceutical Limited | ||
2022/10/21 | Phase 1 | Recruiting | |||
2022/08/05 | Not Applicable | UNKNOWN | Xiangya Hospital of Central South University |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Biofrontera Inc. | 70621-101 | TOPICAL | 100 mg in 1 g | 11/19/2021 | |
| NX DEVELOPMENT CORP | 71469-231 | ORAL | 1500 mg in 1 1 | 2/15/2019 | |
| Medexus Pharma, Inc. | 59137-231 | ORAL | 1500 mg in 1 1 | 1/10/2024 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 12/13/2011 | ||
Authorised | 9/7/2007 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| GLIOLAN, POWDER FOR ORAL SOLUTION, 30 MG/ML | SIN15244P | POWDER, FOR SOLUTION | 30mg/ml | 5/26/2017 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| GLIOLAN POWDER FOR ORAL SOLUTION 30MG/ML | N/A | N/A | N/A | 4/9/2014 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Gliolan (aminolevulinic acid HCl) powder for oral solution, 30 mg/mL, vial | 202549 | Medicine | A | 11/7/2013 | |
| ALACARE 5-aminolevulinic acid hydrochloride 8 mg dermal patch sachet | 223468 | Link Medical Products Pty Ltd T/A Link Pharmaceuticals | Medicine | A | 3/19/2015 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| LEVULAN KERASTICK | 02243933 | Powder For Solution - Topical | 20 % / W/V | 6/3/2004 | |
| GLEOLAN | medexus pharmaceuticals inc. | 02504928 | Powder For Solution - Oral | 1.5 G / VIAL | 2/22/2021 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.